A protein linked to slow-growing brain tumors coming back
Original title: TNFAIP6, an independent prognostic monitor and therapy target, promoted low-grade glioma recurrence and progression via JAK3-STAT6 signaling.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on tumor cells in the lab and on computer data.
The short version
Lab work points to a protein that may help low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary grow and return.
What was studied. Researchers studied a protein called TNFAIP6 in low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They used computer analysis of existing data, machine learning, and tests on tumor cells grown in the lab.
What they found. TNFAIP6 looked like a reliable marker for how low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary turns out over time. In cell tests, it directly drove tumor cells to grow, spread into nearby tissue, and move. These effects were tied to a cell signaling pathway called JAK3-STAT6.
What this means, and what it doesn't
What it could mean: Doctors may one day have a new way to judge how a low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary will behave. It also gives drug makers a possible target to aim at. For now, it does not change any care you can get today.
What it doesn't mean: This is early lab work. The tests were done on cells in a dish and on data from past patients. No drug for this target has been tested in people. There is no proof it helps anyone live longer or feel better. This is not a cure, and it is far from everyday care.
Source: PubMed, March 6, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.